(CBLS) Elevation Series Trust - Ratings and Ratios
Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US53656F6491 • Equity Hedged
CBLS: Equities, Stocks, Shares, Securities, Depository Receipts, Longs, Shorts
The Elevation Series Trust (NYSE ARCA: CBLS) is an actively managed exchange-traded fund (ETF) designed to capitalize on both upward and downward market movements by employing a long-short equity strategy. The fund seeks to achieve its investment objective by identifying and investing in securities with above-average financial characteristics, undervalued assets, or growth potential, while also taking short positions in securities expected to decline in value. Under normal market conditions, the ETF allocates at least 80% of its net assets, plus borrowings for investment purposes, to equity securities, including common stocks and depositary receipts. This approach allows the fund to hedge against market downturns while seeking to generate returns in various market conditions.
From a technical standpoint, CBLS is currently trading below its 20-day and 50-day simple moving averages (SMA) of 27.31 and 27.20, respectively, but above its 200-day SMA of 25.92. This suggests short-term underperformance relative to its recent averages, though it remains above its longer-term trend. The Average True Range (ATR) of 0.34 indicates relatively low volatility. With an average daily trading volume of 1975 shares over the past 20 days, the fund exhibits limited liquidity, which may impact execution for larger trades. Its assets under management (AUM) total $44.69 million, reflecting a smaller-sized ETF in the equity hedged category.
3-Month Forecast (Based on Technical and Fundamental Data): - Technical Outlook: CBLS may face near-term resistance at its 50-day SMA (27.20) and 20-day SMA (27.31). Support is likely to hold at its 200-day SMA (25.92). Given the low ATR of 0.34, price movements are expected to remain subdued, with a potential trading range between 25.50 and 27.50. - Fundamental Outlook: The funds small AUM and low trading volume may limit its ability to capitalize on market inefficiencies, potentially leading to modest returns. However, its hedged strategy could provide downside protection if broader market conditions deteriorate.Additional Sources for CBLS ETF
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
CBLS ETF Overview
Market Cap in USD | 40m |
Category | Equity Hedged |
TER | 2.59% |
IPO / Inception | 2020-11-12 |
CBLS ETF Ratings
Growth Rating | 24.3 |
Fundamental | - |
Dividend Rating | 50.4 |
Rel. Strength | 5.18 |
Analysts | - |
Fair Price Momentum | 24.33 USD |
Fair Price DCF | - |
CBLS Dividends
Dividend Yield 12m | 0.73% |
Yield on Cost 5y | 0.95% |
Annual Growth 5y | 46.06% |
Payout Consistency | 100.0% |
CBLS Growth Ratios
Growth Correlation 3m | -62.8% |
Growth Correlation 12m | 61.4% |
Growth Correlation 5y | 0.4% |
CAGR 5y | 6.61% |
CAGR/Max DD 5y | 0.20 |
Sharpe Ratio 12m | 1.42 |
Alpha | 6.85 |
Beta | 0.862 |
Volatility | 18.94% |
Current Volume | 12.7k |
Average Volume 20d | 2k |
As of May 01, 2025, the stock is trading at USD 26.82 with a total of 12,655 shares traded.
Over the past week, the price has changed by +1.31%, over one month by +2.62%, over three months by +0.34% and over the past year by +17.67%.
Neither. Based on ValueRay Analyses, Elevation Series Trust is currently (May 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 24.33 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CBLS as of May 2025 is 24.33. This means that CBLS is currently overvalued and has a potential downside of -9.28%.
Elevation Series Trust has no consensus analysts rating.
According to ValueRays Forecast Model, CBLS Elevation Series Trust will be worth about 27.7 in May 2026. The stock is currently trading at 26.82. This means that the stock has a potential upside of +3.24%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 27.7 | 3.2% |